Japan and China Dominate Asian Active Pharmaceutical Ingredients Market: companiesandmarkets.com

LONDON--(BUSINESS WIRE)-- The market for active pharmaceutical ingredients (APIs) is highest in the US, followed by Europe and Asia Pacific – the geographic market reporting fastest growth. According to a new report on companiesandmarkets.com, revenue growth in the Asia-Pacific API market is likely to increase at a rate of 9.6% p/a between 2010-2016, following a rate of 6.7% between 2005-2010.

Active Pharmaceutical Ingredients (API) Market in Asia-Pacific to 2016 - The Merchant Market for Generics Continues to Grow as the Competition Increases

Manufacturing of active pharmaceutical ingredients is moving from established Western markets to more emerging regions, particularly India and China. Fluctuating prices of raw materials in these countries is a cause for concern for many API production companies, as when material costs are high, profit margins are eroded – a factor which could influence growth in the Asia-Pacific API market.

In 2010, generic active pharmaceutical ingredients represented the largest share of the Asia-Pacific API market, at 71.5%, with innovator APIs accounting for the rest. The Chinese and Indian API markets have a lesser share of innovator APIs, while Japan has a much larger share. In terms of revenue, Japan and China are the highest contributors to the API market in Asia-Pacific, with 42.8% and 20.8%, respectively. India accounts for 10.3%, while South Korea holds an 8.1% share of the market.

Influential companies profiled within the Asia-Pacific active pharmaceutical ingredients market include AstraZeneca International, GlaxoSmithKline Pharmaceuticals, Novartis, Pfizer Inc and Sanofi-Aventis.

The 88 page Asia-Pacific API research report provides an in-depth explanation of the structure and dynamics of the marketplace, incorporating historic and forecast data from 2005-2016. The API markets of India, China, Japan and South Korea are also analysed individually, and include discussion of trends, growth drivers/barriers, SWOT analysis, therapeutic categories and product types, as well as other market influencing factors.

Report Details:


Companies & Markets
Paul Chapman
Press Office
[email protected]
London (UK): +44 (0) 203 086 8600

KEYWORDS:   United Kingdom  Europe  Asia Pacific

INDUSTRY KEYWORDS:   Health  Pharmaceutical